Clinical data | |
---|---|
Trade names | Amidate, Hypnomidate, Tomvi |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 76% |
Metabolism | Ester hydrolysis in plasma and liver |
Elimination half-life | 75 minutes |
Excretion | Urine (85%) and Bile duct (15%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.046.700 |
Chemical and physical data | |
Formula | C14H16N2O2 |
Molar mass | 244.294 g·mol−1 |
3D model (JSmol) | |
Melting point | 67 °C (153 °F) |
Boiling point | 392 °C (738 °F) |
| |
| |
(verify) |
Etomidate[3] (USAN, INN, BAN; marketed as Amidate) is a short-acting intravenous anaesthetic agent used for the induction of general anaesthesia and sedation[4] for short procedures such as reduction of dislocated joints, tracheal intubation, cardioversion and electroconvulsive therapy. It was developed at Janssen Pharmaceutica in 1964 and was introduced as an intravenous agent in 1972 in Europe and in 1983 in the United States.[5]
The most common side effects include venous pain on injection and skeletal muscle movements.[6]